Table 3

Standardized dataset for the cost-effectiveness models in rotavirus vaccination: vaccine characteristics (Sources: [1-5,7,15,20,28], expert opinions)

Afr

Sear

Amr

Eur

Notes


Efficacy, assuming a 2-dose schedule at 2 & 3 months (1 dose only between brackets)

Mild

52% (52%)

52% (52%)

52% (52%)

87% (87%)

Moderate

55% (54%)

55% (54%)

55% (54%)

92% (90%)

Severe

60% (54%)

60% (54%)

60% (54%)

100% (90%)

Waning of efficacy (annual)

Mild & moderate

0.63

0.63

0.63

0.63

multiply each next year

Severe

0.83

0.83

0.83

0.83

multiply each next year

Coverage

Dose 1

50%

50%

50%

50%

Dose 2

40%

40%

40%

40%

20 years after introduction

80%

80%

80%

96%

for both doses

Coverage improvement

linear

linear

linear

linear

Per-dose vaccine costs (2 doses)

2009-2014

7.5

7.5

7.5

45

2015 & beyond

4

4

4

45


Postma et al. BMC Medicine 2011 9:84   doi:10.1186/1741-7015-9-84

Open Data